Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

Yarrow Bioscience, Inc.

YARWNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 5:07 PM ESTFiling CIK 1566044Accession 0001193125-26-463818
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Yarrow Bioscience, Inc.
Company CIK
0001566044
Street
470 James Street, Suite 007
City
New Haven
State / country code
CT
Postal code
06513

Statement details

Amendment number
1
Security class
Common Stock, $0.0001 par value
Event date
09/30/2026
Rule designation
Rule 13d-1(c)

Reporting person 1

Name
Perceptive Advisors LLC
Citizenship / organization
DE
Reporting person type
IA
Group designation
b
Aggregate amount owned
1,600,647
Percent of class
9.99
Sole voting power
0
Shared voting power
1,600,647
Sole dispositive power
0
Shared dispositive power
1,600,647
Aggregate excludes certain shares
N

Reporting person 2

Name
Joseph Edelman
Citizenship / organization
X1
Reporting person type
IN
Group designation
b
Aggregate amount owned
1,600,647
Percent of class
9.99
Sole voting power
0
Shared voting power
1,600,647
Sole dispositive power
0
Shared dispositive power
1,600,647
Aggregate excludes certain shares
N

Reporting person 3

Name
Perceptive Life Sciences Master Fund, Ltd.
Citizenship / organization
E9
Reporting person type
CO
Group designation
b
Aggregate amount owned
1,600,647
Percent of class
9.99
Sole voting power
0
Shared voting power
1,600,647
Sole dispositive power
0
Shared dispositive power
1,600,647
Aggregate excludes certain shares
N

Item 1

Issuer

Yarrow Bioscience, Inc.

Principal executive office address

470 James Street, Suite 007, New Haven, Connecticut, 06513

Item 2

Citizenship

Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.

Filing person

The names of the persons filing this report (collectively, the "Reporting Persons") with respect to the Common Stock, $0.0001 par value (the "Common Stock") of Yarrow Bioscience, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")

Principal business or residence address

The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003

Item 3

Not applicable indication

Y

Item 4

Percent of class

Perceptive Advisors: 9.99% Mr. Edelman: 9.99% Master Fund: 9.99%

Amount beneficially owned

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 15,234,944 shares of Common Stock outstanding as of November 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2026, and assume the exercise of pre-funded warrants (the "Pre-Funded Warrants") held by the Reporting Persons for 787,549 shares of Common Stock. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock or any Pre-Funded Warrants. The Master Fund directly holds 813,098 shares of Common Stock and 967,361 Pre-Funded Warrants immediately exercisable for shares of Common Stock at an exercise price of $0.0001 per share, subject to the Beneficial Ownership Limitation (as defined below). The terms of the Pre-Funded Warrants provide that the Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation permits the Reporting Persons to exercise Pre-Funded Warrants for an aggregate of not more than 787,549 shares of Common Stock. In providing the beneficial ownership information set forth herein, the Reporting Persons have assumed that the aggregate remaining Pre-Funded Warrants held by the Reporting Persons are not exercisable due to the Beneficial Ownership Limitation. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.

Sole voting power

Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

Shared voting power

Perceptive Advisors: 1,600,647 Mr. Edelman: 1,600,647 Master Fund: 1,600,647

Sole dispositive power

Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

Shared dispositive power

Perceptive Advisors: 1,600,647 Mr. Edelman: 1,600,647 Master Fund: 1,600,647

Item 5

Not applicable indication

Y

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature 1

Reporting person
Perceptive Advisors LLC
Signed
/s/ Joseph Edelman
Title
Joseph Edelman, Managing Member
Date
11/16/2026

Signature 2

Reporting person
Joseph Edelman
Signed
/s/ Joseph Edelman
Title
Joseph Edelman
Date
11/16/2026

Signature 3

Reporting person
Perceptive Life Sciences Master Fund, Ltd.
Signed
/s/ Joseph Edelman
Title
Joseph Edelman, Managing Member
Date
11/16/2026

Company context

Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potentially first-in-class anti-thyroid stimulating hormone receptor (“TSHR”) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both GD and TED. For more information, visit www.yarrowbioscience.com.

Current securities

Historical securities (1)

Recent company filings

  1. SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding Yarrow Bioscience, Inc.Nov 16, 2026
  2. SCHEDULE 13G - filed by AMERIPRISE FINANCIAL INC regarding Yarrow Bioscience, Inc.Nov 16, 2026
  3. S-8 filingNov 13, 2026
  4. SCHEDULE 13G/A - filed by Nantahala Capital Management, LLC regarding Yarrow Bioscience, Inc.Nov 13, 2026
  5. 10-Q filingNov 13, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.